AI-designed drug for inflammatory bowel disease enters human clinical trials: ' A significant need '

Inflammatory bowel disease (IBD) impacts 1.6 million people in the U.S. — and a new -generated drug could help alleviate symptoms. Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed IBD drug — ISM5411 — has entered…#insilicomedicine #hongkong #newyorkcity #insilico #phd #alexzhavoronkov #ism5411 #foxnewsdigital #mayoclinic #iv
Source: Reuters: Health - Category: Consumer Health News Source Type: news